Cargando…

Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses

Pancreatic cancer is a highly malignant tumor with poor prognosis. Currently available Western medical management strategies are unable to prolong the survival time and reduce the mortality of patients with pancreatic cancer. Traditional Chinese medicine has achieved promising results in many clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Wang, Qiuyuan, Zhang, Peitong, Zhang, Ruoqi, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475193/
https://www.ncbi.nlm.nih.gov/pubmed/36120323
http://dx.doi.org/10.3389/fphar.2022.896017
_version_ 1784789859108388864
author Wang, Jing
Wang, Qiuyuan
Zhang, Peitong
Zhang, Ruoqi
He, Jie
author_facet Wang, Jing
Wang, Qiuyuan
Zhang, Peitong
Zhang, Ruoqi
He, Jie
author_sort Wang, Jing
collection PubMed
description Pancreatic cancer is a highly malignant tumor with poor prognosis. Currently available Western medical management strategies are unable to prolong the survival time and reduce the mortality of patients with pancreatic cancer. Traditional Chinese medicine has achieved promising results in many clinical studies. This systematic review and meta-analysis (SR/MA) aimed to explore the benefits and evaluate the quality of evidence of traditional Chinese medicine-based interventions for preventing and treating pancreatic cancer. A systematic search of eight databases for SRs/MAs of randomized controlled trials on traditional Chinese medicine treatment for pancreatic cancer was conducted (from inception to April 2022). The methodological quality of the SRs/MAs was assessed using AMSTAR 2.0, and the quality of evidence was evaluated using the GRADE guide. Nine SRs/MAs, including 145 randomized controlled trials, were considered eligible for this study. The literature were published between 2014 and 2022. The sample size of randomized controlled trials in the MAs ranged from 336 to 1,989. The methodological quality of the nine studies was critically low. Among the 59 outcome indicators of the nine SRs/MAs, seven, 33, and 19 had moderate-, low-, and critically low-quality evidence, respectively, while high-quality evidence was not identified. The results for the long-term indicators, short-term indicators, and adverse reactions in the SRs/MAs displayed consistencies and differences. In conclusion, the methodological and evidence quality of the current evidence is generally low, highlighting the need for additional focus on implementation processes. Some evidence with moderate quality validated that several specific traditional Chinese medicine were optimum for improving the short-term clinical efficacy. However, more objective and high-quality investigations are warranted to verify the efficacy of traditional Chinese medicine for pancreatic cancer.
format Online
Article
Text
id pubmed-9475193
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94751932022-09-16 Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses Wang, Jing Wang, Qiuyuan Zhang, Peitong Zhang, Ruoqi He, Jie Front Pharmacol Pharmacology Pancreatic cancer is a highly malignant tumor with poor prognosis. Currently available Western medical management strategies are unable to prolong the survival time and reduce the mortality of patients with pancreatic cancer. Traditional Chinese medicine has achieved promising results in many clinical studies. This systematic review and meta-analysis (SR/MA) aimed to explore the benefits and evaluate the quality of evidence of traditional Chinese medicine-based interventions for preventing and treating pancreatic cancer. A systematic search of eight databases for SRs/MAs of randomized controlled trials on traditional Chinese medicine treatment for pancreatic cancer was conducted (from inception to April 2022). The methodological quality of the SRs/MAs was assessed using AMSTAR 2.0, and the quality of evidence was evaluated using the GRADE guide. Nine SRs/MAs, including 145 randomized controlled trials, were considered eligible for this study. The literature were published between 2014 and 2022. The sample size of randomized controlled trials in the MAs ranged from 336 to 1,989. The methodological quality of the nine studies was critically low. Among the 59 outcome indicators of the nine SRs/MAs, seven, 33, and 19 had moderate-, low-, and critically low-quality evidence, respectively, while high-quality evidence was not identified. The results for the long-term indicators, short-term indicators, and adverse reactions in the SRs/MAs displayed consistencies and differences. In conclusion, the methodological and evidence quality of the current evidence is generally low, highlighting the need for additional focus on implementation processes. Some evidence with moderate quality validated that several specific traditional Chinese medicine were optimum for improving the short-term clinical efficacy. However, more objective and high-quality investigations are warranted to verify the efficacy of traditional Chinese medicine for pancreatic cancer. Frontiers Media S.A. 2022-09-01 /pmc/articles/PMC9475193/ /pubmed/36120323 http://dx.doi.org/10.3389/fphar.2022.896017 Text en Copyright © 2022 Wang, Wang, Zhang, Zhang and He. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Jing
Wang, Qiuyuan
Zhang, Peitong
Zhang, Ruoqi
He, Jie
Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses
title Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses
title_full Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses
title_fullStr Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses
title_full_unstemmed Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses
title_short Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses
title_sort efficacy and safety of traditional chinese medicine for the treatment of pancreatic cancer: an overview of systematic reviews and meta-analyses
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475193/
https://www.ncbi.nlm.nih.gov/pubmed/36120323
http://dx.doi.org/10.3389/fphar.2022.896017
work_keys_str_mv AT wangjing efficacyandsafetyoftraditionalchinesemedicineforthetreatmentofpancreaticcanceranoverviewofsystematicreviewsandmetaanalyses
AT wangqiuyuan efficacyandsafetyoftraditionalchinesemedicineforthetreatmentofpancreaticcanceranoverviewofsystematicreviewsandmetaanalyses
AT zhangpeitong efficacyandsafetyoftraditionalchinesemedicineforthetreatmentofpancreaticcanceranoverviewofsystematicreviewsandmetaanalyses
AT zhangruoqi efficacyandsafetyoftraditionalchinesemedicineforthetreatmentofpancreaticcanceranoverviewofsystematicreviewsandmetaanalyses
AT hejie efficacyandsafetyoftraditionalchinesemedicineforthetreatmentofpancreaticcanceranoverviewofsystematicreviewsandmetaanalyses